Literature DB >> 22285548

Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo.

Ikuhiko Nakase1, Yusuke Konishi, Masashi Ueda, Hideo Saji, Shiroh Futaki.   

Abstract

We investigated the biodistribution of arginine-rich cell-penetrating peptides (CPPs) in tumor-xenografted nude mice after intravenous injection of fluorescently labeled CPPs using in vivo imaging. The CPPs used included HIV-1 Tat (48-60), penetratin, and the L- and D-enantiomers of oligoarginines (8, 12, and 16 residues), all of which are reported to have high cell penetration. Among the tested peptides, high accumulation in tumors was observed for the D-form of octaarginine (r8), and glycosaminoglycans played a key role. Injection of an r8-doxorubicin conjugate (4mg doxorubicin/kg) effectively suppressed tumor proliferation, with no significant decrease in mouse weight, whereas administration of doxorubicin itself (6mg/kg), yielding a similar degree of tumor-growth suppression, resulted in significant weight loss. These results suggest the potential of r8 as a prototypic tumor-targeting vector.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285548     DOI: 10.1016/j.jconrel.2012.01.016

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

1.  Cancer cell surface induced peptide folding allows intracellular translocation of drug.

Authors:  Scott H Medina; Joel P Schneider
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

2.  Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

Authors:  Gu Xiao; George K Annor; Kimberly Fung; Outi Keinänen; Brian M Zeglis; Jill Bargonetti
Journal:  Mol Pharm       Date:  2020-12-08       Impact factor: 4.939

3.  Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression.

Authors:  Masashi Ueda; Hayato Hisada; Takashi Temma; Yoichi Shimizu; Hiroyuki Kimura; Masahiro Ono; Yuji Nakamoto; Kaori Togashi; Hideo Saji
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

Review 4.  Amphiphilic macromolecules on cell membranes: from protective layers to controlled permeabilization.

Authors:  E Marie; S Sagan; S Cribier; C Tribet
Journal:  J Membr Biol       Date:  2014-06-06       Impact factor: 1.843

5.  Blocking TIR Domain Interactions in TLR9 Signaling.

Authors:  Artur Javmen; Henryk Szmacinski; Joseph R Lakowicz; Vladimir Y Toshchakov
Journal:  J Immunol       Date:  2018-06-18       Impact factor: 5.422

Review 6.  Biosafe nanoscale pharmaceutical adjuvant materials.

Authors:  Shubin Jin; Shengliang Li; Chongxi Wang; Juan Liu; Xiaolong Yang; Paul C Wang; Xin Zhang; Xing-Jie Liang
Journal:  J Biomed Nanotechnol       Date:  2014-09       Impact factor: 4.099

Review 7.  Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.

Authors:  Dalal AlDeghaither; Brandon G Smaglo; Louis M Weiner
Journal:  J Clin Pharmacol       Date:  2015-03       Impact factor: 3.126

8.  Development of an oxygen-sensitive degradable peptide probe for the imaging of hypoxia-inducible factor-1-active regions in tumors.

Authors:  Masashi Ueda; Kei Ogawa; Azusa Miyano; Masahiro Ono; Shinae Kizaka-Kondoh; Hideo Saji
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

Review 9.  Targeting malignant mitochondria with therapeutic peptides.

Authors:  Jonathan E Constance; Carol S Lim
Journal:  Ther Deliv       Date:  2012-08

10.  Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection.

Authors:  Sangho Lim; Nancy C Kirkiles-Smith; Jordan S Pober; Alfred L M Bothwell; Je-Min Choi
Journal:  Biomaterials       Date:  2018-08-21       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.